Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split to Avoid Nasdaq Delisting
ERNA is trading near its 52-week low of $0.184 (22% below the low) on light trading volume (0.1× avg).
Summary
Ernexa Therapeutics announced a 1-for-25 reverse stock split, effective May 4, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. This action directly addresses the high risk of Nasdaq delisting and going concern doubts previously highlighted in the company's last 10-K. While shareholders approved a reverse split range on March 27 and an information statement was filed on April 13, this press release provides the definitive ratio and effective date. Reverse stock splits are typically viewed negatively by the market as they often signal financial distress and a struggle to maintain exchange listing, despite the company's framing of it as a step to strengthen its financial foundation. The split will significantly reduce outstanding shares from approximately 29.15 million to 1.17 million. Investors should monitor the stock's ability to maintain the minimum bid price post-split and the company's progress on its strategic priorities.
At the time of this announcement, ERNA was trading at $0.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.18 to $4.02. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.